<DOC>
	<DOCNO>NCT00130780</DOCNO>
	<brief_summary>This phase II , single institution trial patient clinical Stage IB-IIIA NSCLC ( T1-3N0-2M0 ) resectable lung tumor . The primary goal study show addition bevacizumab cisplatin-based chemotherapy neoadjuvant set non-squamous cell carcinomas improve rate pathologic downstaging , correlate survival . Downstaging defined decrease final pathologic stage compare clinical stage induction therapy .</brief_summary>
	<brief_title>Multimodality Treatment Patients With Resectable Non-Small Cell Lung Cancer ( NSCLC ) - BEACON Study : Bevacizumab Chemotherapy Operable NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Pathologic confirmation NSCLC Memorial SloanKettering Cancer Center ( MSKCC ) Stages IB , IIA , IIB IIIA ( T13N02M 0 ) NSCLC Patients must candidate resection curative intent . Measurable disease , define least one lesion accurately measure least two dimension Age &gt; = 18 year Karnofsky performance status &gt; = 70 % Normal marrow function : leukocyte &gt; = 3,000/µl ; absolute neutrophil count ≥ 1,500µl ; platelet &gt; = 100,000 µl ; hemoglobin &gt; = 9gm/dl . Adequate renal function , creatinine &lt; = 1.3 mg/dl calculate creatinine clearance &gt; = 60ml/min CockcroftGault equation use parameter age , weight ( kg ) , baseline serum creatinine ( mg/dl ) Adequate hepatic function : total bilirubin within normal limit ; AST &lt; = 1.5 X upper limit normal ( UNL ) ; ALT &lt; = 1.5 X UNL ; alkaline phosphatase &lt; = 1.5 X UNL . Women childbearing age must negative urine blood pregnancy test . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Patients must ability understand willingness sign write informed consent document . Eligibility criterion group B : Patients SQUAMOUS CELL carcinoma patient NONSQUAMOUS CELL tumor large central tumor proximity significant blood vessel history hemoptysis assign group B ( preoperative chemotherapy alone without bevacizumab ) . Prior chemotherapy radiation therapy NSCLC Prior treatment bevacizumab agent specifically target vascular endothelial growth factor ( VEGF ) Patients history severe hypersensitivity reaction docetaxel ( Taxotere ) drug formulate polysorbate 80 Patients know hypersensitivity recombinant human antibodies Patients must receive investigational agent . History stroke transient ischemic attack ( TIA ) . History myocardial infarction unstable angina within past 12 month . Patients report hear deficit baseline , even require hear aid intervention , interfere activity daily life ( Common Terminology Criteria Adverse Events [ CTCAE ] grade 2 high ) Peripheral neuropathy &gt; grade 1 . Uncontrolled hypertension Esophageal varix , nonhealing ulcer , wound , bone fracture Known HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction study drug . Other serious illness medical condition include unstable cardiac disease require treatment , history significant neurologic psychiatric disorder ( include psychotic disorder , dementia , seizure ) , symptomatic diverticulitis , active uncontrolled infection . Women pregnant breastfeed Psychiatric illness social situation would limit compliance study requirement Exclusion criterion group A : Patients SQUAMOUS CELL carcinoma , large central tumor proximity significant blood vessel , history hemoptysis ( exclude group A ( preoperative chemotherapy plus bevacizumab ) ; patient assign group B ( preoperative chemotherapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Multi-modality treatment lung cancer</keyword>
	<keyword>Carcinoma , Squamous Cell</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>BEACON</keyword>
	<keyword>05-052</keyword>
</DOC>